Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females aged ≥ 18 to \< 65 years at the time of vaccination~* Non pregnant/ non lactating females~Exclusion Criteria:~* Hypersensitivity to influenza vaccine or allergy to any components of the Study Vaccines~* Vaccination against influenza in the previous 6 months~* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality~* Known history of Guillain-Barré Syndrome;~* Clinical signs of active infection and/or an oral temperature of ≥ 37.8 oC.~* History of neurological disorders or seizures~* Confirmed or suspected immunosuppressive condition or a previously diagnosed immunodeficiency disorder~* Current or recent immunosuppressive or immunomodulative therapy, including systemic corticosteroids~* Administration of immunoglobulins and/or any blood products;~* Participation in a clinical trial or use of an investigational compound;~* Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior;~* Participants indicated to receive an influenza vaccine on an annual basis according to the local public health recommendations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).